GuidelineChest2013
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Guideline in Chest, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Pooled it
- A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.Cancer prevention research (Philadelphia, Pa.) · 2016Trial
- Article
- DNA Methylation and Gene Expression of the Cysteinyl Leukotriene Receptors as a Prognostic and Metastatic Factor for Colorectal Cancer Patients.International journal of molecular sciences · 2023Article
- Omega 3 supplementation reduces C-reactive protein, prostaglandin EFrontiers in nutrition · 2022Article
- Article
- Associations of aspirin, statins and metformin with lung cancer risk and related mortality.Breathe (Sheffield, England) · 2021Article
- Cancer Prevention by Natural Products Introduced into the Diet-Selected Cyclitols.International journal of molecular sciences · 2020Review
- Recommendations on complementary and alternative medicine within S3 guidelines in oncology: systematic quality assessment of underlying methodology.Journal of cancer research and clinical oncology · 2020Article
- Houttuynia cordata Thunb. and its bioactive compound 2-undecanone significantly suppress benzo(a)pyrene-induced lung tumorigenesis by activating the Nrf2-HO-1/NQO-1 signaling pathway.Journal of experimental & clinical cancer research : CR · 2019Article
- Can we use interleukin-1β blockade for lung cancer treatment?Translational lung cancer research · 2018Article
- CHL1 gene polymorphisms increase lung cancer susceptibility.Oncotarget · 2018Article
- Review
- Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.Oncotarget · 2016Article
- Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients.Scientific reports · 2016Article
- Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.Trends in pharmacological sciences · 2016Review
- An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management.American journal of respiratory and critical care medicine · 2015Article
- Indeterminate pulmonary nodules: risk for having or for developing lung cancer?Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Intensive care unit and lung cancer: when should we intubate?Journal of thoracic disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most common cause of cancer death in men and women in the United States. Cigarette smoking is the main risk factor. Former smokers are at a substantially increased risk of developing lung cancer compared with lifetime never smokers. Chemoprevention refers to the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention.
methodsArticles of primary, secondary, and tertiary prevention trials were reviewed and summarized to obtain recommendations.
resultsNone of the phase 3 trials with the agents β-carotene, retinol, 13-cis-retinoic acid, α-tocopherol, N-acetylcysteine, acetylsalicylic acid, or selenium has demonstrated beneficial and reproducible results. To facilitate the evaluation of promising agents and to lessen the need for a large sample size, extensive time commitment, and expense, surrogate end point biomarker trials are being conducted to assist in identifying the most promising agents for later-stage chemoprevention trials. With the understanding of important cellular signaling pathways and the expansion of potentially important targets, agents (many of which target inflammation and the arachidonic acid pathway) are being developed and tested which may prevent or reverse lung carcinogenesis.
conclusionsBy integrating biologic knowledge, additional early-phase trials can be performed in a reasonable time frame. The future of lung cancer chemoprevention should entail the evaluation of single agents or combinations that target various pathways while working toward identification and validation of intermediate end points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.